vmireavizВестник медицинского института «РЕАВИЗ». Реабилитация, Врач и ЗдоровьеBulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)2226-762X2782-1579РЕАВИЗ10.20340/vmi-rvz.2023.3.CLIN.12vmireaviz-811Research ArticleКлиническая медицинаClinical medicineСТАТЬЯ ОТОЗВАНА: Индуцированные химиотерапией широкореактивные аутоантитела в лечении злокачественных новообразованийRETRACTED: Chemotherapy-induced broadly reactive autoantibodies in the treatment of malignancieshttps://orcid.org/0000-0003-4235-9452ШанинаЕ. В.ShaninaE. V.

Шанина Елена Вадимовна, д-р естественных наук, научный руководитель лаборатории

ул. Жечка Карамфилова, д. 74, Бургас, Болгария

Elena V. Shanina, Dr. rer. nat., Scientific Director of the Laboratory

74 Zhechka Karamfilova str., Burgas, Bulgaria

elsshanin@gmail.comhttps://orcid.org/0000-0001-7373-9760БрёкерФ.BrekerF.

Брёкер Феликс, д-р естественных наук, технический руководитель лаборатории

ул. Жечка Карамфилова, д. 74, Бургас, Болгария

Felix Brecker, Dr. rer. nat., Technical Head of the Laboratory

74 Zhechka Karamfilova str., Burgas, Bulgaria

felixbroecker@gmx.nethttps://orcid.org/0000-0003-2883-5117ЛысовН. А.LysovN. A.

Лысов Николай Александрович, д-р мед. наук, профессор, академик РАМТН, лауреат губернской премии в области науки и техники, почётный работник высшего профессионального образования Минобрнауки РФ, вице-президент Российской Ассоциации гериатров и геронтологов, почётный ректор

ул. Чапаевская, д. 227, Самара, 443001

Nikolay A. Lysov, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Medical Sciences, laureate of the Provincial Prize in Science and Technology, Honorary Worker of Higher Professional Education of the Ministry of Education and Science of the Russian Federation, Vice-President of the Russian Association of Geriatricians and Gerontologists, Honorary Rector

227 Chapaevskaya str., Samara, 443001

lysovn@mail.ruhttps://orcid.org/0000-0001-9554-987XШанинВ. Ю.ShaninV. Yu.

Шанин Вадим Юльевич, д-р мед. наук, лауреат Премии В. Вернадского, член-корреспондент МАЭН, профессор кафедры хирургии

ул. Чапаевская, д. 227, Самара, 443001

Vadim Y. Shanin, Dr. Sci. (Med.), V. Vernadsky Prize laureate, Corresponding Member of the MAEN, Professor of the Department of Surgery

227 Chapaevskaya str., Samara, 443001

prd88@yandex.ruhttps://orcid.org/0000-0002-7713-4926ПономареваЮ. В.PonomarevaYu. V.

Пономарева Юлия Вячеславовна, д-р мед. наук, директор ООО «АРТБИО», директор НИИ Медицинских персонифицированных биотехнологий

ул. Чапаевская, д. 227, Самара, 443001

Yulia V. Ponomareva, Dr. Sci. (Med.), Director of ARTBIO LLC, Director of the Research Institute of Medical Personalized Biotechnologies

227 Chapaevskaya str., Samara, 443001

artbio_com@mail.ruhttps://orcid.org/0000-0002-1350-0704СупильниковА. А.Supil'nikovA. A.

Супильников Алексей Александрович, канд. мед. наук, доцент, первый проректор по научной работе, заведующий кафедрой морфологии и патологии

ул. Чапаевская, д. 227, Самара, 443001

Alexey A. Supilnikov, Cand. Sci. (Med.), Docent, First Vice-Rector for Scientific Work, Head of the Department of Morphology and Pathology

227 Chapaevskaya str., Samara, 443001

a.a.supilnikov@reaviz.onlineОнкоВакс Тераностикс LLCБолгарияOncoVax Theranostics Co.LtdBulgariaМедицинский университет «Реавиз»РоссияMedical University “Reaviz”Russian Federation202317072023133104109Copyright © Шанина Е.В., Брёкер Ф., Лысов Н.А., Шанин В.Ю., Пономарева Ю.В., Супильников А.А., 20232023Шанина Е.В., Брёкер Ф., Лысов Н.А., Шанин В.Ю., Пономарева Ю.В., Супильников А.А.Shanina E.V., Breker F., Lysov N.A., Shanin V.Y., Ponomareva Y.V., Supil'nikov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestnik.reaviz.ru/jour/article/view/811

СТАТЬЯ ОТОЗВАНА

Цель исследования - оценить связь между химиотерапией и аутоиммунными реакциями у пациентов с метастатическим раком толстой кишки. Известно, что рак и аутоиммунность взаимосвязаны, но до сих пор было неясно, насколько именно химиотерапия способствует развитию аутоиммунных реакций. Изучили уровни иммуноглобулина M (IgM) в ответ на введение различных тканей человека до и во время адъювантной химиотерапии. Пациентам было проведено семь циклов химиотерапии по схеме FOLFIRI плюс цетуксимаб. Уровни IgM против исследуемых тканей увеличились уже после первого цикла химиотерапии и продолжали возрастать во время второго и третьего циклов. Затем аутоиммунные реакции начали снижаться с четвёртого по седьмой циклы, однако оставались повышенными по сравнению с исходным уровнем для большинства исследуемых тканей. Наши результаты свидетельствуют о том, что химиотерапия может вызывать широкий спектр аутоиммунных реакций. Мониторинг самореактивных IgM-ответов во время лечения может помочь предотвратить или облегчить побочные эффекты, связанные с аутоиммунитетом.

RETRACTED ARTICLE

The aim of the study was to evaluate the relationship between chemotherapy and autoimmune reactions in patients with metastatic colorectal cancer. Cancer and autoimmunity are known to be interrelated, but until now it has been unclear to what extent chemotherapy specifically contributes to autoimmune reactions. We studied immunoglobulin M (IgM) levels in response to the administration of various human tissues before and during adjuvant chemotherapy. Patients received seven cycles of chemotherapy with the FOLFIRI plus cetuximab regimen. IgM levels against the tested tissues increased already after the first cycle of chemotherapy and continued to increase during the second and third cycles. Autoimmune responses then began to decrease from the fourth to seventh cycles, but remained elevated from baseline for most of the study tissues. Our results suggest that chemotherapy can induce a wide range of autoimmune reactions. Monitoring self-reactive IgM responses during treatment may help prevent or alleviate side effects associated with autoimmunity.

рак толстой кишкиаденокарциномахимиотерапиятоксичностьаутоиммунитетIgMэкспресс-диагностикаагглютинационный анализcolorectal canceradenocarcinomachemotherapytoxicityautoimmunityIgMrapid diagnosisagglutination assayReferencesJohnson A.K. Repercussions of occult malignancy – an etiologic basis for rheumatic disease. Med Hypotheses. 2013;80:447-51. https://doi.org/10.1016/j.mehy.2012.12.038Johnson A.K. Repercussions of occult malignancy – an etiologic basis for rheumatic disease. Med Hypotheses. 2013;80:447-51. https://doi.org/10.1016/j.mehy.2012.12.038Naschitz J.E. Rheumatic syndromes: clues to occult neoplasia. Curr Opin Rheumatol. 2001;13:62-6. https://doi.org/10.1097/00002281-200101000-00010Naschitz J.E. Rheumatic syndromes: clues to occult neoplasia. Curr Opin Rheumatol. 2001;13:62-6. https://doi.org/10.1097/00002281-200101000-00010Chatham M., Niravath P. Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature. Cureus. 2021;13:e20203. https://doi.org/10.7759/cureus.20203Chatham M., Niravath P. Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature. Cureus. 2021;13:e20203. https://doi.org/10.7759/cureus.20203Mandal S., Pile K., Chacko R.T., Danda D. Malignancy and autoimmunity: causally or casually related? Int J Rheum Dis. 2014;17:601-5. https://doi.org/10.1111/1756-185X.12536Mandal S., Pile K., Chacko R.T., Danda D. Malignancy and autoimmunity: causally or casually related? Int J Rheum Dis. 2014;17:601-5. https://doi.org/10.1111/1756-185X.12536Albert M.L., Darnell R.B. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer. 2004;4:36-44. https://doi.org/10.1038/nrc1255Albert M.L., Darnell R.B. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer. 2004;4:36-44. https://doi.org/10.1038/nrc1255Joseph C.G., Darrah E., Shah A.A. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343:152-7. https://doi.org/10.1126/science.1246886Joseph C.G., Darrah E., Shah A.A. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343:152-7. https://doi.org/10.1126/science.1246886Teng M.W., Smyth M.J. Cancer. Can cancer trigger autoimmunity? Science. 2014;343:147-8. https://doi.org/10.1126/science.1249486Teng M.W., Smyth M.J. Cancer. Can cancer trigger autoimmunity? Science. 2014;343:147-8. https://doi.org/10.1126/science.1249486De Jonge H., Iamele L., Maggi M., Pessino G., Scotti C. Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues. Cancers (Basel). 2021;13:813. https://doi.org/10.3390/cancers13040813De Jonge H., Iamele L., Maggi M., Pessino G., Scotti C. Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues. Cancers (Basel). 2021;13:813. https://doi.org/10.3390/cancers13040813Wilson A.L., Moffitt L.R., Duffield N., Rainczuk A., Jobling T.W., Plebanski M., Stephens A.N. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2018;27:183-192. https://doi.org/10.1158/1055-9965.EPI-17-0752Wilson A.L., Moffitt L.R., Duffield N., Rainczuk A., Jobling T.W., Plebanski M., Stephens A.N. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2018;27:183-192. https://doi.org/10.1158/1055-9965.EPI-17-0752Roney M.SI., Lanagan C., Sheng Y.H. et al. IgM and IgA augmented autoantibody signatures improve early-stage detection of colorectal cancer prior to nodal and distant spread. Clin Transl Immunology. 2021;10:e1330. https://doi.org/10.1002/cti2.1330Roney M.SI., Lanagan C., Sheng Y.H. et al. IgM and IgA augmented autoantibody signatures improve early-stage detection of colorectal cancer prior to nodal and distant spread. Clin Transl Immunology. 2021;10:e1330. https://doi.org/10.1002/cti2.1330Ocadlikova D., Lecciso M., Isidori A. et al. Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Front Oncol. 2019;9:1004. https://doi.org/10.3389/fonc.2019.01004Ocadlikova D., Lecciso M., Isidori A. et al. Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Front Oncol. 2019;9:1004. https://doi.org/10.3389/fonc.2019.01004Yamada N., Yamasaki K., Yamamoto N., Kuki I., Sakuma H., Hara J. Chemotherapy-induced autoimmune-mediated encephalitis during germinoma treatment. Brain Dev. 2021;43:967-971. https://doi.org/10.1016/j.braindev.2021.05.010Yamada N., Yamasaki K., Yamamoto N., Kuki I., Sakuma H., Hara J. Chemotherapy-induced autoimmune-mediated encephalitis during germinoma treatment. Brain Dev. 2021;43:967-971. https://doi.org/10.1016/j.braindev.2021.05.010Strenger V., Merth G., Lackner H. et al. Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents-a single centre experience of 20 years. Ann Hematol. 2018;97:989-998. https://doi.org/10.1007/s00277-018-3254-4Strenger V., Merth G., Lackner H. et al. Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents-a single centre experience of 20 years. Ann Hematol. 2018;97:989-998. https://doi.org/10.1007/s00277-018-3254-4Kim M.J., Ye Y.M., Park H.S., Suh C.H. Chemotherapy-related arthropathy. J Rheumatol. 2006;33:1364-8.Kim M.J., Ye Y.M., Park H.S., Suh C.H. Chemotherapy-related arthropathy. J Rheumatol. 2006;33:1364-8.Wang L., Wei Y., Fang W., Lu C., Chen J., Cui G., Diao H. Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer. Cell Physiol Biochem. 2017;44:1038-1050. https://doi.org/10.1159/000485404Wang L., Wei Y., Fang W., Lu C., Chen J., Cui G., Diao H. Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer. Cell Physiol Biochem. 2017;44:1038-1050. https://doi.org/10.1159/000485404Narang A., Qiao F., Atkinson C., et al. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury, drive secondary injury by activating complement. J Neuroinflammation. 2017;14:120. https://doi.org/10.1186/s12974-017-0894-6Narang A., Qiao F., Atkinson C., et al. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury, drive secondary injury by activating complement. J Neuroinflammation. 2017;14:120. https://doi.org/10.1186/s12974-017-0894-6Needham E.J., Stoevesandt O., Thelin E.P. et al. Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. J Immunol. 2021;207:90-100. https://doi.org/10.4049/jimmunol.2001309Needham E.J., Stoevesandt O., Thelin E.P. et al. Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. J Immunol. 2021;207:90-100. https://doi.org/10.4049/jimmunol.2001309Chakraborty S., Karasu E., Huber-Lang M. Complement After Trauma: Suturing Innate and Adaptive Immunity. Front Immunol. 2018; 9:2050. https://doi.org/10.3389/fimmu.2018.02050Chakraborty S., Karasu E., Huber-Lang M. Complement After Trauma: Suturing Innate and Adaptive Immunity. Front Immunol. 2018; 9:2050. https://doi.org/10.3389/fimmu.2018.02050Fuentes-Antrás J., Peinado P., Guevara-Hoyer K., Del Arco C.D., Sánchez-Ramón S., Aguado C. Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma. Hematol Oncol Stem Cell Ther. 2020;S1658-3876(20)30098-4. https://doi.org/10.1016/j.hemonc.2020.04.006Fuentes-Antrás J., Peinado P., Guevara-Hoyer K., Del Arco C.D., Sánchez-Ramón S., Aguado C. Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma. Hematol Oncol Stem Cell Ther. 2020;S1658-3876(20)30098-4. https://doi.org/10.1016/j.hemonc.2020.04.006Sotzny F., Filgueiras I.S., Kedor C. et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front Immunol. 2022;13:981532. https://doi.org/10.3389/fimmu.2022.981532Sotzny F., Filgueiras I.S., Kedor C. et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front Immunol. 2022;13:981532. https://doi.org/10.3389/fimmu.2022.981532Shanin V.Y. Immunologically substance, process for preparing same, bioprobe, pharmaceutical composition, diagnostics and treatment methods. WO2012053928A1. 2012, EA 018848B1.Shanin V.Y. Immunologically substance, process for preparing same, bioprobe, pharmaceutical composition, diagnostics and treatment methods. WO2012053928A1. 2012, EA 018848B1.

The authors declare that there are no conflicts of interest present.